Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study

References

• Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the global burden of disease study 2010. Lancet Glob Health. 2013;1:e259–e281. doi:10.1016/S2214-109X(13)70089-525104492
   PubMed Web of Science ®Google Scholar
• Stroke Association, UK. State of the Nation: stroke statistics. [document on the internet]; 2017 Available from: https://www.stroke.org.uk/resources/state-nation-stroke-statistics. Accessed 1116, 2018.
   Google Scholar
• Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the general practice research database. BMJ Open. 2011;1:e000269. doi:10.1136/bmjopen-2011-000269
   PubMed Web of Science ®Google Scholar
• Koton S, Schneider AL, Rosamond WD, et al. Stroke incidence and mortality trends in us communities, 1987 to 2011. JAMA. 2014;312:259–268. doi:10.1001/jama.2014.769225027141
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Scarborough P, Smeeton NC, Allender S. The incidence of all stroke and stroke subtype in the United Kingdom, 1985 to 2008: a systematic review. BMC Public Health. 2010;10:539. doi:10.1186/1471-2458-10-53920825664
   PubMed Web of Science ®Google Scholar
• Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev. 2009;3:CD002091. doi:10.1002/14651858.CD002091.pub219588332
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–767. doi:10.1016/S0140-6736(04)15690-015016485
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559. doi:10.1056/NEJMoa06189416899775
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818. doi:10.1093/eurheartj/ehr15821712404
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013;2014(129):S1–S45. doi: 10.1161/01.cir.0000437738.63853.7a
   Web of Science ®Google Scholar
• NICE guideline. Cardiovascular disease: risk assessment and reduction, including lipid modification; 2014 Available from: https://www.nice.org.uk/guidance/cg181/chapter/1-recommendations. Accessed 1116, 2018.
   Google Scholar
• National Institute for Health and Care Excellence. Quality and outcomes framework (QOF) indicator development programme; 2013 Available from: https://www.nice.org.uk/media/default/standards-and-indicators/qof-indicator-assessment-report.Pdf. Accessed 1116, 2018.
   Google Scholar
• Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017;48:2723–2730. doi:10.1161/STROKEAHA.117.01814028916672
   PubMed Web of Science ®Google Scholar
• Chen PS, Cheng CL, Kao Yang YH, Li YH. Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J. 2016;80:731–737. doi:10.1253/circj.CJ-15-075326742588
   PubMed Web of Science ®Google Scholar
• Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397–401. doi:10.1161/STROKEAHA.109.56695020075360
   PubMed Web of Science ®Google Scholar
• Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011;77:1182–1190. doi:10.1212/WNL.0b013e31822f042321900638
   PubMed Web of Science ®Google Scholar
• Wawruch M, Zatko D, Wimmer G Jr., et al. Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke. Pharmacoepidemiol Drug Saf. 2017;26:201–207. doi:10.1002/pds.414827935151
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827–836. doi:10.1093/ije/dyv09826050254
   PubMed Web of Science ®Google Scholar
• Ministry of Housing, Communities & Local Government. English Indices of Deprivation. London: Gov.Uk.; 2015 Available from: http://www.Gov.Uk/government/statistics/english-indices-of-deprivation-2015. Accessed 1116, 2018.
   Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561. doi:10.1016/S0140-6736(16)31357-527616593
   PubMed Web of Science ®Google Scholar
• Cassell A, Edwards D, Harshfield A, et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018;68:e245–e251. doi:10.3399/bjgp18X69546529530918
   PubMed Web of Science ®Google Scholar
• Zou GY, Donner A. Extension of the modified poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013;22:661–670. doi:10.1177/096228021142775922072596
   PubMed Web of Science ®Google Scholar
• Ni Chroinin D, Asplund K, Asberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44:448–456. doi:10.1161/STROKEAHA.112.66827723287777
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Schwamm LH, Smith EE, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41:1508–1513. doi:10.1161/STROKEAHA.109.57361820508182
   PubMed Web of Science ®Google Scholar
• Sjolander M, Eriksson M, Glader EL. Social stratification in the dissemination of statins after stroke in sweden. Eur J Clin Pharmacol. 2013;69:1173–1180. doi:10.1007/s00228-012-1454-823187964
   PubMed Web of Science ®Google Scholar
• Grau AJ, Eicke M, Biegler MK, et al. Quality monitoring of acute stroke care in rhineland-palatinate, germany, 2001–2006. Stroke. 2010;41:1495–1500. doi:10.1161/STROKEAHA.110.58223920522811
   PubMed Web of Science ®Google Scholar
• Dregan A, Toschke MA, Wolfe CD, et al. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health. 2011;11:86. doi:10.1186/1471-2458-11-8621299872
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Farkouh ME, Mefford M, et al. Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69:2696–2706. doi:10.1016/j.jacc.2017.03.58528571633
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65:270–277. doi:10.1016/j.jacc.2014.09.08825614424
   PubMed Web of Science ®Google Scholar
• Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in scottish primary care. Stroke. 2005;36:1771–1775. doi:10.1161/01.STR.0000173398.99163.9e16040591
   PubMed Web of Science ®Google Scholar
• Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the swedish stroke register. Stroke. 2010;41:1338–1342. doi:10.1161/STROKEAHA.110.58020920522818
   PubMed Web of Science ®Google Scholar
• Eissa A, Krass I, Bajorek BV. Use of medications for secondary prevention in stroke patients at hospital discharge in australia. Int J Clin Pharm. 2014;36:384–393. doi:10.1007/s11096-013-9908-324519632
   PubMed Web of Science ®Google Scholar
• Raine R, Wong W, Ambler G, et al. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ. 2009;338:b1279. doi:10.1136/bmj.b90219372118
   PubMed Web of Science ®Google Scholar
• Li X, Gao Y, Li J, et al. Underuse of statins in patients with atherosclerotic ischemic stroke in China. Chin Med J (Engl). 2012;125:1703–1707. doi: 10.3760/cma.j.issn.0366-6999.2012.10.00522800887
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;2016(253):281–344. doi: 10.1016/j.atherosclerosis.2016.08.018
   Web of Science ®Google Scholar
• Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA. 2000;283:3230–3235. doi:10.1001/jama.283.24.323010866871
   PubMed Web of Science ®Google Scholar
• Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69:2293–2300. doi:10.1016/j.jacc.2017.02.06428473134
   PubMed Web of Science ®Google Scholar
• Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825–834. doi: 10.7326/0003-4819-135-9-200111060-0001211694107
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261. doi:10.1056/NEJMoa070620117984166
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–1239. doi:10.1016/S0140-6736(08)61240-418757089
   PubMed Web of Science ®Google Scholar
• van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res. 2006;71:443–454. doi:10.1016/j.cardiores.2006.04.01116730683
   PubMed Web of Science ®Google Scholar
• Vargas JI, Arrese M, Shah VH, Arab JP. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep. 2017;19:43. doi:10.1007/s11894-017-0584-728752475
   PubMedGoogle Scholar
• Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6:712–722. doi:10.1038/nrcardio.2009.16319770848
   PubMed Web of Science ®Google Scholar
• Cox AM, McKevitt C, Rudd AG, Wolfe CD. Socioeconomic status and stroke. Lancet Neurol. 2006;5:181–188. doi:10.1016/S1474-4422(06)70351-916426994
   PubMed Web of Science ®Google Scholar
• Jamison J, Sutton S, Mant J, De Simoni A. Barriers and facilitators to adherence to secondary stroke prevention medications after stroke: analysis of survivors and caregivers views from an online stroke forum. BMJ Open. 2017;7:e016814. doi:10.1136/bmjopen-2017-016814
   Web of Science ®Google Scholar
• Izuka NJ, Alexander MA, Balasooriya-Smeekens C, Mant J, De Simoni A. How do stroke survivors and their carers use practitioners‘ advice on secondary prevention medications? Qualitative study of an online forum. Fam Pract. 2017;34:612–620. doi:10.1093/fampra/cmx02328398553
   PubMed Web of Science ®Google Scholar